Table 4. Effects of topical ocular bradykinin on IOP of Cynomolgus monkey eyes.
| Cynomolgus monkey studies |
Monkey IOP changes after topical ocular dosing |
||
|---|---|---|---|
| Time post- administration (hours) | IOP (mmHg) | IOP change (% of control) | |
|
Normal pressure monkey eyes |
0 h |
27.1±1.0 |
0 |
| BK (100 µg) group |
1 h |
27.1±1.1 |
0.2±2.5% |
| BK (100 µg) group |
3 h |
26.6±0.7 |
−1.0±2.9% |
| BK (100 µg) group |
6 h |
27.2±1.1 |
0.8±2.3% |
| BK (100 µg) group |
24 h |
27.8±1.4 |
2.4±3.3% |
|
Ocular hypertensive monkey eyes |
0 h |
36.8±1.6 |
0 |
| BK (100 µg) group |
1 h |
35.9±1.8 |
−2.6±1.5% |
| BK (100 µg) group |
3 h |
35.7±1.6 |
−2.7±3.3% |
| BK (100 µg) group |
6 h |
36.6±1.7 |
−0.4±3.0% |
| BK (100 µg) group |
24 h |
35.3±1.6 |
−4.1±2.3% |
|
Cabergoline
(50 µg) group* |
0 h |
34.7±3.0 |
0 |
|
1 h |
nd |
-16.0% |
|
|
3 h |
nd |
-30.4% |
|
|
7 h |
nd |
-28.8% |
|
| 24 h | nd | -27.3% | |
Data are mean ± SEM from twelve conscious Cynomolgus monkeys with one normotensive (control eye) and one eye rendered hypertensive with laser trabeculoplasty. * Data for cabergoline (positive control agent) are from Ref. Thirty for comparison with another topical ocularly administered compound in the ocular hypertensive eyes of nine conscious Cynomolgus monkeys; nd represents not determined.